Equity Profile

CRVS

Corvus Pharmaceuticals, Inc.

Health CareBiotechnology$1.0B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Corvus Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for cancer and autoimmune diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CRVS Q2-2026 Earnings Preview

Context

Company Snapshot

Corvus Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for cancer and autoimmune diseases. With a market cap of $1 billion, the company operates in the health care sector, which is increasingly important as advancements in biotechnology continue to shape treatment options for patients.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-58.69%

Avg Stock Reaction

-2.23%

Last Quarter Recap

In Q1-2026, Corvus reported an EPS of -$0.15, slightly missing the estimate of -$0.14. The stock reacted negatively, dropping 5.57% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Corvus's upcoming earnings report, especially given the company's focus on innovative therapies. However, the lack of analyst estimates adds uncertainty.

Bull Case

If Corvus can demonstrate improved clinical trial results or unexpected revenue growth, it could lead to a positive reassessment of the stock.

Bear Case

Conversely, if the company continues to miss earnings expectations or fails to provide clear guidance, it may reinforce bearish sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

The EPS figure will be crucial in determining whether the company can turn around its recent performance and meet investor expectations.

What is the revenue outlook for the next quarter?

A clear revenue outlook will help investors gauge the company's growth potential and market demand for its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be overly pessimistic about Corvus's potential for recovery, underestimating the impact of recent clinical trial advancements.

Supporting Evidence

The options market is pricing a 41.16% move, suggesting that traders expect significant volatility, which could indicate a potential positive surprise.

The historical average move of 5% suggests that the stock may not react as dramatically as the options imply.

Key Risk

If the EPS comes in better than -$0.10, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Corvus can improve its financial performance after a series of misses.

Bull Confirmed If

An EPS of -$0.10 or better would confirm the bull case and indicate improved financial health.

Bear Confirmed If

An EPS worse than -$0.15 would reinforce the bear case and suggest ongoing challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±41.16%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty around the earnings report.

Options are pricing ±40.2% while CRVS has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

96.0%

Calls (48K)P/C Ratio: 0.69Puts (16K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 14 of 29 (48%)

This setup has occurred 30 times across Health Care in the last 2 years. 14 of 29 faded and 15 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.8%, with a raw directional average of -1.7% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Corvus beats expectations, history suggests the stock could rise by an average of 2.4%, confirming a positive shift in sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further clarity on future guidance.

Miss

If the company misses again, history suggests a potential decline of around 6.87%, reinforcing negative sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on clinical trial results that could impact future revenue.
2Management's commentary on cost management and operational efficiency.
3Insights into market demand for Corvus's therapies.
4Any guidance on future earnings expectations.
5Discussion of strategic partnerships or collaborations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Corvus Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for cancer and autoimmune diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CRVS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-58.69%

Avg Stock Reaction

-2.23%

Last Quarter Recap

In Q1-2026, Corvus reported an EPS of -$0.15, slightly missing the estimate of -$0.14. The stock reacted negatively, dropping 5.57% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Corvus's upcoming earnings report, especially given the company's focus on innovative therapies. However, the lack of analyst estimates adds uncertainty.

Bull Case

If Corvus can demonstrate improved clinical trial results or unexpected revenue growth, it could lead to a positive reassessment of the stock.

Bear Case

Conversely, if the company continues to miss earnings expectations or fails to provide clear guidance, it may reinforce bearish sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

The EPS figure will be crucial in determining whether the company can turn around its recent performance and meet investor expectations.

What is the revenue outlook for the next quarter?

A clear revenue outlook will help investors gauge the company's growth potential and market demand for its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be overly pessimistic about Corvus's potential for recovery, underestimating the impact of recent clinical trial advancements.

Supporting Evidence

The options market is pricing a 41.16% move, suggesting that traders expect significant volatility, which could indicate a potential positive surprise.

The historical average move of 5% suggests that the stock may not react as dramatically as the options imply.

Key Risk

If the EPS comes in better than -$0.10, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Corvus can improve its financial performance after a series of misses.

Bull Confirmed If

An EPS of -$0.10 or better would confirm the bull case and indicate improved financial health.

Bear Confirmed If

An EPS worse than -$0.15 would reinforce the bear case and suggest ongoing challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±41.16%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty around the earnings report.

Options are pricing ±40.2% while CRVS has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

96.0%

Calls (48K)P/C Ratio: 0.69Puts (16K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 14 of 29 (48%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Corvus beats expectations, history suggests the stock could rise by an average of 2.4%, confirming a positive shift in sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further clarity on future guidance.

Miss

If the company misses again, history suggests a potential decline of around 6.87%, reinforcing negative sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on clinical trial results that could impact future revenue.
2Management's commentary on cost management and operational efficiency.
3Insights into market demand for Corvus's therapies.
4Any guidance on future earnings expectations.
5Discussion of strategic partnerships or collaborations.